个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lu Kepeng[1] * ; Liao Qian-Qian[2] * ; Zhu Ke-Wei[3,4] * ; Yao Ying[5] ; Cui Xiao-Jiao[6] ; Chen Peng[4] ; Bi Ying[7] ; Zhong Meng[8] ; Zhang Hao[2] ; Tang Jing-Cai[9] ; Yu Qin[2] ; Yue Jia-Kui[10] ; He Hui[11] ; Zhu Ze-Feng[12] ; Cai Ze-Zheng[13] ; Yang Zhe[14] ; Zhang Wei[15,17] ; Dong Yang-Tao[2] ; Wei Qiu-Mian[2] ; He Xuegai[16] ;
机构： [1]Department of Pharmacy, The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang, China [2]Department of Pharmacy, People’s Hospital of Guilin, No.12 Civilization Road, Xiangshan District, Guilin, China [3]Office of Pharmacovigilance, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, No. 88 Yunxiang Road Tonghe Street, Baiyun District, Guangzhou 510515, Guangdong Province, China [4]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, No. 110 Xiangya Road, Changsha, China [5]Department of Pharmacy, People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, No. 301 Zhengyuan North Street, Jinfeng District, Yinchuan, China [6]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, No. 32 West Second Section, 1st Ring Road, Qingyang District, Chengdu, China [7]Department of Pharmacy, Nanchang Hongdu Hospital of TCM, No. 128 Xiangshan North Road, Donghu District, Nanchang, China [8]Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District, Luzhou, China [9]Administration Office of Medication Clinical Trial, People’s Hospital of Guilin, No.12 Civilization Road, Xiangshan District, Guilin, China [10]Department of Pharmacy, The Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, China [11]Department of Pharmacology, Renshou People’s Hospital, No. 177, Section 1, Longtan Avenue, Huairen Street, Renshou County, Meishan, China [12]Department of Pharmacy, Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Guilin, China [13]Department of Pharmacology, People’s Hospital of Qiandongnan Prefecture, No. 31 Shaoshan South Road, Kaili, Qiandongnan Miao and Dong Autonomous Prefecture, China [14]Department of Pharmacy, North China Medical Health Group Xingtai General Hospital, No. 202 Bayi Street, Xingtai, China [15]Department of Pharmacy, Yangquan Coal Industry (Group) General Hospital, No. 218 North Street, Mining Area, Yangquan, China [16]Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang 471003, Henan Province, China [17]Department of Pharmacy, The First Affiliated Hospital of Hainan Medical University, No.31 Longhua Road, Longhua District, Haikou, China
出处：
DOI： 10.1007/s12325-023-02717-5
ISSN：

关键词： Rivaroxaban Elderly patients Olderpatients Venous thromboembolism (VTE) Real-world Bleeding Nomogram Majorbleeding Non-major clinically relevant(NMCR) Direct oral anticoagulant (DOAC)

摘要：
Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). Rivaroxaban is a direct oral anticoagulant (DOAC) inhibiting activated coagulation factor X (FXa), and exerts several advantages in the treatment of VTE compared to conventional therapy. However, the efficacy and safety of rivaroxaban in elderly patients with VTE was still poorly understood.The study was carried out using an observational and non-interventional approach. A total of 576 patients aged ≥ 60 years with newly diagnosed VTE were included in the study. All patients received rivaroxaban with recommended treatment duration of ≥ 3 months for secondary prevention. In addition, 535 elderly patients with various diseases except VTE were included in the study in a retrospective and randomized way.The total bleeding rate was 12.2% (70/576). Major bleeding and non-major clinically relevant (NMCR) bleeding occurred in 4 (0.69%) patients and 5 (0.87%) patients, respectively. The rate of recurrent VTE was 5.4%. The mean level of D-dimers was increased by 467.2% in the elderly patients with VTE compared with the elderly patients without VTE. The elderly patients with VTE receiving rivaroxaban at a dose of 10 mg once daily (n = 134) had lower risk for bleeding (3.7% vs 14.7%; P = 0.001) and a similar rate of recurrent VTE (4.5% vs 5.7%; P = 0.596) as compared to the elderly patients with VTE receiving rivaroxaban at higher doses including 15 mg once daily and 20 mg once daily (n = 442). In addition, age, concomitant aspirin, hemoglobin, activated partial thromboplastin time (APTT), and rivaroxaban doses were independent predictive factors for bleeding events.The study suggested that a dose of 10 mg once daily should be the priority in elderly patients with VTE receiving long-term rivaroxaban anticoagulation therapy in view of reduced bleeding risk.© 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.

基金：
This work was supported by the Health Commission of Henan Province [grant number LHGJ20200577], and was sponsored by Henan provincial Medical Science and Technology Research Project [grant number LHGJ20200577].
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：研究与实验 3 区 药学
最新[2025]版：
大类 | 3 区 医学
小类 | 2 区 药学 3 区 医学：研究与实验
JCR分区：
出版当年[2022]版：
Q2 PHARMACOLOGY & PHARMACY Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Pharmacy, The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang, China
共同第一作者：
通讯作者：
通讯机构： [3]Office of Pharmacovigilance, GuangZhou BaiYunShan Pharmaceutical Holdings CO., LTD. BaiYunShan Pharmaceutical General Factory, No. 88 Yunxiang Road Tonghe Street, Baiyun District, Guangzhou 510515, Guangdong Province, China [4]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, No. 110 Xiangya Road, Changsha, China
推荐引用方式(GB/T 7714)：
Lu Kepeng,Liao Qian-Qian,Zhu Ke-Wei,et al.Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study[J].ADVANCES IN THERAPY.2024,41(1):451-463.doi:10.1007/s12325-023-02717-5.
APA：
Lu Kepeng,Liao Qian-Qian,Zhu Ke-Wei,Yao Ying,Cui Xiao-Jiao...&He Xuegai.(2024).Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.ADVANCES IN THERAPY,41,(1)
MLA：
Lu Kepeng,et al."Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study".ADVANCES IN THERAPY 41..1(2024):451-463

相关文献

[1]紫龙金片治疗老年非小细胞肺癌的真实世界疗效分析 [2]建立真实世界数据与研究技术规范,促进中国真实世界证据的生产与使用 [3]急性上消化道出血患者既往出血次数与90 d全因死亡和再出血的关系：一项真实世界研究 [4]建立真实世界数据与研究技术规范，促进中国真实世界证据的生产与使用 [5]Predictors of Chronic Postsurgical Pain in Elderly Patients Undergoing Hip Arthroplasty: A Multi-Center Retrospective Cohort Study. [6]Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China [7]A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment [8]基于真实世界数据评价治疗结局的观察性研究设计技术规范 [9]从湿辨治抗血管内皮生长因子治疗后视网膜静脉阻塞黄斑水肿的疗效观察 [10]重新认识真实世界数据研究:更新与展望

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号